New combo therapy aims to shrink tumors before esophageal cancer surgery
NCT ID NCT05659251
Summary
This study is testing whether adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery is safe and effective for people with a type of esophageal cancer that can be removed by surgery. The goal is to see if this combination treatment can better shrink the tumor and kill cancer cells before the operation, which may help lower the chance of the cancer coming back later. Researchers will follow 48 patients to measure tumor response, safety, and long-term survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China, 310009, China
Conditions
Explore the condition pages connected to this study.